01862nas a2200301   4500000000100000008004100001260001300042653002900055653002600084653002100110653001400131653001500145653001800160653002300178653001100201653002800212653001600240653001200256653003400268653001300302653002000315653001500335100001200350245012600362300000900488490000700497520105600504       1984                            d  c1984 Feb10aAntigen-Antibody Complex10aArthritis, Rheumatoid10aBurkitt Lymphoma10aCell Line10aCollectins10aComplement C310aGlomerulonephritis10aHumans10aImmune Complex Diseases10aImmunoassay10aleprosy10aLupus Erythematosus, Systemic10aLymphoma10aSerum Globulins10aVasculitis1 aArndt R00a[Demonstration of C3-binding circulating immune complexes using Raji, conglutinin and anti-C3 assays--a critical review].  a3-110 v123 a<p>There remains no doubt at the present time, that the appearance of circulating immune complexes in illness accompanying vasculitis and for glomerulonephritis correlates with the severity of disease. Moreover, immune complexes are of diagnostic importance where infections with a chronic development or neoplastic diseases are concerned. The choice of IC test system should incorporate their essential biological functions and identify those IC that activate the complement cascade both by the classical and the alternative route. The detection of IC bound C3 cleavage products (C3b, C3bi, C3d) represents the key to identification of a wide range of IC. Of the presently available methods Raji cell test, conglutinin- and anti C3-IC assay, on critical appraisal, the anti C3-IC assay represents the most applicable way of defining complement binding IC. The advantage of this system is that appreciable disturbances and limitations that influence other systems do not affect the antigen-antibody reaction which is the core of the anti C3 assay.</p>